RE:RE:RE:RE:RE:RE:RE:RE:Interview with Dr. BieberThe ongoing transformation of the company led by Bieber in dialogue with Pullan;
The long awaited second deal with top-10 pharma with non-disclosed terms which most likely is descent - reflected by actions like having Bieber/Pullan onboard and be able to pay for it;
The next product on the market rather sooner than later, because abbvie already started product development pre-deal, should trigger milestones and royalty;
The upcoming pet diabetes treatment deal this year;
The start of anti-aging / anti-wrinkle clinical trial going head to head with Botox this autumn;
The goal of up listing reflected by company actions;
The contiuned development of anti-virals and anti-cellulite;
The spin-out of backlog compounds;
The ability to attract institutional investors because of R+F, AbbVie/Allergan, Pullan, Bieber and what's mentioned above;
Considering all of this it's painful for the long term investors to experience the current low share price, but for new investors that starts fresh it's probably one of the best investment on the market today!